WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 412649
CAS#: 181296-84-4 (free base)
Description: Omigapil (free base) is a drug that was developed by Novartis and tested in clinical trials for its ability to help treat Parkinson's disease and amyotrophic lateral sclerosis
MedKoo Cat#: 412649
Name: Omigapil (free base)
CAS#: 181296-84-4 (free base)
Chemical Formula: C19H17NO
Exact Mass: 275.131
Molecular Weight: 275.35
Elemental Analysis: C, 82.88; H, 6.22; N, 5.09; O, 5.81
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 181296-84-4 (free base) 200189-97-5 (maleate)
Synonym: Omigapil (free base); CGP3466; CGP-3466; CGP 3466
IUPAC/Chemical Name: N-(dibenzo[b,f]oxepin-10-ylmethyl)-N-methylprop-2-yn-1-amine
InChi Key: QLMMOGWZCFQAPU-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H17NO/c1-3-12-20(2)14-16-13-15-8-4-6-10-18(15)21-19-11-7-5-9-17(16)19/h1,4-11,13H,12,14H2,2H3
SMILES Code: CN(CC1=Cc2c(Oc3c1cccc3)cccc2)CC#C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 275.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Yu Q, Sali A, Van der Meulen J, Creeden BK, Gordish-Dressman H, Rutkowski A, Rayavarapu S, Uaesoontrachoon K, Huynh T, Nagaraju K, Spurney CF. Omigapil treatment decreases fibrosis and improves respiratory rate in dy(2J) mouse model of congenital muscular dystrophy. PLoS One. 2013 Jun 6;8(6):e65468. doi: 10.1371/journal.pone.0065468. PMID: 23762378; PMCID: PMC3675144.
2: Gale TV, Horton TM, Hoffmann AR, Branco LM, Garry RF. Host Proteins Identified in Extracellular Viral Particles as Targets for Broad-Spectrum Antiviral Inhibitors. J Proteome Res. 2019 Jan 4;18(1):7-17. doi: 10.1021/acs.jproteome.8b00204. Epub 2018 Nov 5. PMID: 30351952.
3: Sen T, Saha P, Sen N. Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β. Sci Signal. 2018 Mar 20;11(522):eaao6765. doi: 10.1126/scisignal.aao6765. PMID: 29559585; PMCID: PMC6371980.
4: Erb M, Meinen S, Barzaghi P, Sumanovski LT, Courdier-Früh I, Rüegg MA, Meier T. Omigapil ameliorates the pathology of muscle dystrophy caused by laminin- alpha2 deficiency. J Pharmacol Exp Ther. 2009 Dec;331(3):787-95. doi: 10.1124/jpet.109.160754. Epub 2009 Sep 16. PMID: 19759319.
5: Meinen S, Lin S, Thurnherr R, Erb M, Meier T, Rüegg MA. Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice. EMBO Mol Med. 2011 Aug;3(8):465-79. doi: 10.1002/emmm.201100151. Epub 2011 Jun 15. PMID: 21674808; PMCID: PMC3377088.
6: Sarkozy A, Foley AR, Zambon AA, Bönnemann CG, Muntoni F. LAMA2-Related Dystrophies: Clinical Phenotypes, Disease Biomarkers, and Clinical Trial Readiness. Front Mol Neurosci. 2020 Aug 5;13:123. doi: 10.3389/fnmol.2020.00123. PMID: 32848593; PMCID: PMC7419697.
7: Harraz MM, Snyder SH. Nitric Oxide-GAPDH Transcriptional Signaling Mediates Behavioral Actions of Cocaine. CNS Neurol Disord Drug Targets. 2015;14(6):757-63. doi: 10.2174/1871527314666150529150143. PMID: 26022259; PMCID: PMC4831565.
8: Yacoubian TA, Standaert DG. Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta. 2009 Jul;1792(7):676-87. doi: 10.1016/j.bbadis.2008.09.009. Epub 2008 Oct 1. PMID: 18930814; PMCID: PMC2740981.
9: LeWitt PA. Clinical trials of neuroprotection for Parkinson's disease. Neurology. 2004 Oct 12;63(7 Suppl 2):S23-31. doi: 10.1212/wnl.63.7_suppl_2.s23. PMID: 15477583.
10: Snider NT, Portney DA, Willcockson HH, Maitra D, Martin HC, Greenson JK, Omary MB. Ethanol and Acetaminophen Synergistically Induce Hepatic Aggregation and TCH346-Insensitive Nuclear Translocation of GAPDH. PLoS One. 2016 Aug 11;11(8):e0160982. doi: 10.1371/journal.pone.0160982. PMID: 27513663; PMCID: PMC4981434.
